Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Change in Receivables (2023 - 2025)

Bioharvest Sciences has reported Change in Receivables over the past 3 years, most recently at $1.1 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 75.66% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $865000.0, up 202.45%, while the annual FY2025 figure was $865000.0, 202.45% up from the prior year.
  • Change in Receivables was $1.1 million for Q4 2025 at Bioharvest Sciences, up from $237000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.1 million in Q4 2025 and bottomed at -$360000.0 in Q1 2025.
  • The 3-year median for Change in Receivables is -$92000.0 (2023), against an average of $93100.0.
  • Year-over-year, Change in Receivables skyrocketed 468.39% in 2024 and then crashed 779.25% in 2025.
  • Over 3 years, Change in Receivables stood at -$174000.0 in 2023, then skyrocketed by 468.39% to $641000.0 in 2024, then surged by 75.66% to $1.1 million in 2025.
  • The last three reported values for Change in Receivables were $1.1 million (Q4 2025), $237000.0 (Q3 2025), and -$138000.0 (Q2 2025) per Business Quant data.